What is figur8.me?
FIGUR8 is at the forefront of developing sophisticated wearable musculoskeletal (MSK) technology. The company's innovative solution is designed to precisely identify the root cause of MSK pathology. By providing critical data, FIGUR8 aims to enhance patient-centric recovery pathways throughout the entire care episode, from initial injury to complete rehabilitation. This technology is poised to revolutionize how MSK conditions are diagnosed and managed.
How much funding has figur8.me raised?
figur8.me has raised a total of $19.9M across 3 funding rounds:
Angel/Seed
$7.5M
Debt
$350K
Series A
$12M
Angel/Seed (2019): $7.5M with participation from E14 Fund and P5 Health Ventures
Debt (2020): $350K led by PPP
Series A (2021): $12M supported by E14 Fund, P5 Health Ventures, Taiwania Capital, and Phoenix Venture Partners
Key Investors in figur8.me
E14 Fund
E14 Fund is a venture capital firm affiliated with MIT, specializing in early-stage investments in companies founded by MIT affiliates. They provide capital and resources to foster innovation.
P5 Health Ventures
P5 Health Ventures focuses on investments that enhance healthcare and promote healthier living, with a portfolio including diagnostics and AI solutions.
Taiwania Capital
Taiwania Capital is a venture capital firm investing in early-stage companies, with a focus on enterprise software, AI, IoT, and robotics.
What's next for figur8.me?
With its recent major strategic investment, FIGUR8 is well-positioned to accelerate its growth and further refine its cutting-edge MSK technology. The substantial capital infusion, including $12M from its latest funding round, will likely fuel product development, market expansion, and strategic partnerships. This financing suggests a strong market validation and confidence in FIGUR8's potential to disrupt the healthcare technology landscape, particularly in the realm of remote patient monitoring and recovery analytics.
See full figur8.me company page
